


Modified Form PTO-1449	Atty. Docket No.	Serial No.
	A-579D	09/728,421
	Applicant	
	Yoshinaga, et al	
Filing Date		Group
November 28, 2000		

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)



## U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-	TRANSLATION

## OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)

C1	Attwood, T., "The Babel of Bioinformatics", <i>Science</i> , 290: 471-473, (20 Oct 2000).
C2	Blazar, et al., "Infusion of Anti-B7.1 (CD80) and Anti-B7.2 (CD86) Monoclonal Antibodies Inhibits Murine Graft-Versus-Host Disease Lethality In Part Via Direct Effects on CD4 <sup>+</sup> and CD8 <sup>+</sup> T Cells", <i>Jnl. of Immunol.</i> , 157: 3250-3259 (1996)
C3	Bowie et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 247: 1306-1310, (16 March 1990).
C4	Dai, Z. et al., "The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection", <i>Current Opinion in Immunology 1999 United Kingdom</i> , Vol. 11, No. 5, 504-508, (1999).
C5	Database UNIPROT [Online] Wang, et al.: "ICOS ligand precursor (B7 homolog 2) (B7-H2) (B7-like protein G150) (B7-related protein 1) (B7RP-1) (CD275 antigen)", UNIPROT Assession No. 075144, 15 July 1999.
C6	Database UNIPROT [Online] O'Regan, et al., "ICOS ligand.", UNIPROT Assession No. 042404, 1 January 1998.
C7	Fick, R. B., et al., "Immunotherapy approach to allergic disease", <i>Immunopharmacology</i> , 48: 307-310, (25 July 2000).
C8	Heaney, Liam G., et al., "Severe asthma treatment: need for characterising patients", <i>Lancet</i> , 365: 974-976, (12 March 2005).

EXAMINER:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Modified Form PTO-1449  <b>LIST OF REFERENCES CITED BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No.	A-579D	Serial No.	09/728,421
	Applicant	Yoshinaga, et al		
	Filing Date	November 28, 2000	Group	

**OTHER DOCUMENTS (Including Publisher, Author, Title, Date, Pertinent Pages, Etc.)**

C9	Huang, Ziwei, "Structural chemistry and therapeutic intervention of protein-protein interactions in immune response, human immunodeficiency virus entry, and apoptosis", <i>Pharmacology &amp; Therapeutics</i> , 86: 201-215, (2000).
C10	Ishikawa, et al "Prediction of the coding Sequences of Unidentified Human Genes. X. The Complete Sequences of 100 New cDNA Clones from Brain Which Can Code for Large Proteins <i>in vitro</i> ", <i>DNA Rsh.</i> , 5: 169-176 (1998)
C11	Kahan, Barry D., "Immunosuppressive therapy", <i>Current Opinion in Immunology</i> , 4: 553-559, (1992).
C12	Metzler, et al., "Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28", <i>Nature Structural Biology</i> , 4, No. 7: 527-531, (July 1997).
C13	The Merck Manual of Diagnosis and Therapy, Section 6 – Pulmonary Disorders, Chapter 68, Seventeenth Edition, Published by Merck Research Laboratories, Division of Merck & Co., Inc., Whitehouse Station, NJ, 556-557, (1999).
C14	Schultze, J., et al., "B7-mediated costimulation and the immune response", <i>Blood Reviews 1996 United Kingdom</i> , Vol. 10, No. 2, 111-127, (1996).
C15	Skolnick, Jeffrey, et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", <i>Trends in Biotechnology</i> , 18(1): 34-39, (January 2000).

EXAMINER:	Date Considered:
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	